D.E. Shaw & Co
CRNX icon

D.E. Shaw & Co’s Crinetics Pharmaceuticals CRNX Stock Holding History

D.E. Shaw & Co’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-9,876
Closed -$505K – 4335
2024
Q4 		$505K Sell
9,876
-55,813
-85% -$3.12M ﹤0.01% 3609
2024
Q3 		$3.36M Buy
65,689
+26,123
+66% +$1.35M ﹤0.01% 2285
2024
Q2 		$1.77M Buy
39,566
+32,666
+473% +$1.51M ﹤0.01% 2760
2024
Q1 		$323K Sell
6,900
-10,105
-59% -$395K ﹤0.01% 3694
2023
Q4 		$605K Sell
17,005
-29,440
-63% -$903K ﹤0.01% 3425
2023
Q3 		$1.38M Sell
46,445
-24,145
-34% -$498K ﹤0.01% 2860
2023
Q2 		$1.27M Buy
+70,590
New +$1.41M ﹤0.01% 2941
2023
Q1 		– Sell
-31,417
Closed -$575K – 4519
2022
Q4 		$575K Sell
31,417
-5,738
-15% -$101K ﹤0.01% 3774
2022
Q3 		$730K Buy
37,155
+9,162
+33% +$187K ﹤0.01% 3810
2022
Q2 		$522K Buy
27,993
+12,972
+86% +$259K ﹤0.01% 4064
2022
Q1 		$330K Sell
15,021
-51,761
-78% -$1.05M ﹤0.01% 4600
2021
Q4 		$1.9M Buy
66,782
+24,687
+59% +$609K ﹤0.01% 3400
2021
Q3 		$886K Buy
42,095
+10,863
+35% +$227K ﹤0.01% 3700
2021
Q2 		$589K Buy
+31,232
New +$549K ﹤0.01% 3947
2020
Q3 		– Sell
-14,581
Closed -$255K – 3887
2020
Q2 		$255K Buy
+14,581
New +$249K ﹤0.01% 3687

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

D.E. Shaw & Co's CRNX Position: Q1 2025 in Review

D.E. Shaw & Co sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2025, closing a stake of 9,876 shares — an estimated $505K sold.

D.E. Shaw & Co first reported a position in CRNX in Q2 2020 and held it in 15 quarters. The position peaked at $3.36M in Q3 2024. 227 funds tracked by Wall St. Rank hold CRNX as of Q1 2025.

  • D.E. Shaw & Co reported no remaining Crinetics Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • D.E. Shaw & Co sold 9,876 Crinetics Pharmaceuticals shares in Q1 2025, an estimated $505K.
  • D.E. Shaw & Co first reported a position in Crinetics Pharmaceuticals in Q2 2020 and held it in 15 quarters.
  • D.E. Shaw & Co's Crinetics Pharmaceuticals position peaked at $3.36M in Q3 2024.
  • 227 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2025.

Based on D.E. Shaw & Co's 13F filing for Q1 2025, filed 15 May 2025.